On July 25, 2016 Reuters reported that the drug developer, Ocular Therapeutix, Inc, said the U.S. Food and Drug Administration (the "FDA") had denied approval for its treatment for post-operative eye pain. Ocular said the FDA was concerned about its manufacturing process after a facility inspection, but the letter from the health regulator did not provide any details about the manufacturing deficiencies. Ocular also said there were no clinical issues identified in this letter and expects Dextenza to be approved once the manufacturing concerns were solved. On July 25, 2016 in pre-market trading, Ocular's stock dropped 3% to just $5.01 per share.
If you purchased Ocular shares or if you are aware of any facts relating to this investigation, you can assist this investigation by visiting the firm's site: http://www.bgandg.com/#!ocul/cmaxo. You can also contact Peretz Bronstein or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC: 212-697-6484 or via email firstname.lastname@example.org. Those who inquire by e-mail are encouraged to include their mailing address, email and telephone number.
Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm's expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.
Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Hurwitz
212-697-6484 | email@example.com
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/shareholder-alert-bronstein-gewirtz--grossman-llc-announces-investigation-of-ocular-therapeutix-inc-ocul-300303332.html
SOURCE Bronstein, Gewirtz & Grossman, LLC